Are there clinical trials using miR-21 as a therapeutic target?

Yes — beyond detection, miR-21 is being investigated as a therapeutic target. Several companies are developing antagomirs (synthetic miRNA inhibitors) that block miR-21 function in cancer cells. miR-21 inhibition has shown efficacy in preclinical cancer models by restoring PTEN and other tumor suppressor expression. Additionally, miR-21 is being studied as a prognostic biomarker in clinical trials — patients with high miR-21 expression in tumor tissue or blood may have worse outcomes with certain chemotherapy regimens. This depth of clinical investigation surrounding miR-21 — as a detection marker, prognostic marker, and therapeutic target simultaneously — underscores its central importance in cancer biology and the strength of the scientific foundation behind OncuraKit.